Analysts Offer Insights on Materials Companies: Hecla Mining Company (HL), Nexa Resources SA (NEXA) and Anglogold Ashanti PLC (AU)
Analysts have been eager to weigh in on the Materials sector with new ratings on Hecla Mining Company (HL – Research Report), Nexa Resources SA (NEXA – Research Report) and Anglogold Ashanti PLC (AU – Research Report).
Protect Your Portfolio Against Market Uncertainty
Hecla Mining Company (HL)
In a report issued on May 5, Michael Siperco from RBC Capital maintained a Buy rating on Hecla Mining Company, with a price target of $6.00. The company's shares closed last Wednesday at $4.88, close to its 52-week low of $4.41.
According to TipRanks.com, Siperco is a 5-star analyst with an average return of 17.3% and a 59.0% success rate. Siperco covers the Basic Materials sector, focusing on stocks such as Novagold Resources New, Torex Gold Resources, and Pan American Silver.
Hecla Mining Company has an analyst consensus of Moderate Buy, with a price target consensus of $6.75, representing a 39.2% upside. In a report issued on May 2, Roth MKM also maintained a Buy rating on the stock with a $6.00 price target.
Nexa Resources SA (NEXA)
RBC Capital analyst Sam Crittenden maintained a Hold rating on Nexa Resources SA yesterday and set a price target of $8.00. The company's shares closed last Wednesday at $5.15, close to its 52-week low of $5.04.
According to TipRanks.com, Crittenden is a 5-star analyst with an average return of 16.4% and a 54.3% success rate. Crittenden covers the Basic Materials sector, focusing on stocks such as First Quantum Minerals, Solaris Resources, and Warrior Met Coal.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Nexa Resources SA with a $6.21 average price target, a 15.1% upside from current levels. In a report issued on April 29, BMO Capital also maintained a Hold rating on the stock with a $6.00 price target.
Anglogold Ashanti PLC (AU)
In a report issued on May 5, Josh Wolfson from RBC Capital maintained a Buy rating on Anglogold Ashanti PLC, with a price target of $41.00. The company's shares closed last Wednesday at $43.68.
According to TipRanks.com, Wolfson is a 5-star analyst with an average return of 9.8% and a 66.7% success rate. Wolfson covers the Basic Materials sector, focusing on stocks such as Wheaton Precious Metals, Osisko Gold Royalties, and Sandstorm Gold.
Anglogold Ashanti PLC has an analyst consensus of Moderate Buy, with a price target consensus of $42.20, implying a -1.7% downside from current levels. In a report issued on April 27, J.P. Morgan also maintained a Buy rating on the stock with a $53.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
13 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO – Research Report) and Ramsay Health Care (RMSYF – Research Report). Confident Investing Starts Here: Bio-Rad Laboratories (BIO) RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories on June 5 and set a price target of $381.00. The company's shares closed last Monday at $225.56. According to McNamara 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, SOPHiA GENETICS, and Exact Sciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $316.40 average price target. In a report released today, Steven Wheen from Jarden maintained a Hold rating on Ramsay Health Care, with a price target of A$44.05. The company's shares closed last Thursday at $24.00. According to Wheen is ranked #1103 out of 9627 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $25.09 average price target.
Business Insider
14 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Medtronic (MDT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Illumina (ILMN – Research Report) and Medtronic (MDT – Research Report) with bullish sentiments. Confident Investing Starts Here: Illumina (ILMN) RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina on June 5 and set a price target of $115.00. The company's shares closed last Monday at $84.98, close to its 52-week low of $79.30. According to McNamara has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $107.13 average price target, which is a 28.3% upside from current levels. In a report issued on May 27, Leerink Partners also maintained a Buy rating on the stock. Medtronic (MDT) The company's shares closed last Monday at $87.45. According to Jennings is a 4-star analyst with an average return of 5.3% and a 52.7% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Zimmer Biomet Holdings. Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $95.76, a 9.6% upside from current levels. In a report issued on May 27, Argus Research also maintained a Buy rating on the stock with a $105.00 price target.
Business Insider
15 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Addus Homecare (ADUS) and Cytokinetics (CYTK)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on QuidelOrtho (QDEL – Research Report), Addus Homecare (ADUS – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments. Confident Investing Starts Here: QuidelOrtho (QDEL) In a report issued on June 5, Conor McNamara from RBC Capital maintained a Buy rating on QuidelOrtho, with a price target of $60.00. The company's shares closed last Monday at $30.21, close to its 52-week low of $29.74. According to McNamara is ranked 0 out of 5 stars with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS. QuidelOrtho has an analyst consensus of Moderate Buy, with a price target consensus of $45.00, which is a 48.4% upside from current levels. In a report issued on June 5, Craig-Hallum also maintained a Buy rating on the stock with a $60.00 price target. Addus Homecare (ADUS) In a report released yesterday, Ryan Daniels from William Blair maintained a Buy rating on Addus Homecare. The company's shares closed last Monday at $116.56. According to Daniels is a 4-star analyst with an average return of 8.4% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Pediatrix Medical Group, and Lifestance Health Group. Addus Homecare has an analyst consensus of Strong Buy, with a price target consensus of $135.17, representing a 18.7% upside. In a report issued on June 1, Jefferies also maintained a Buy rating on the stock with a $160.00 price target. Cytokinetics (CYTK) In a report issued on June 5, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company's shares closed last Monday at $33.13. According to Timashev is a 3-star analyst with an average return of 2.9% and a 42.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $75.21 average price target, a 128.3% upside from current levels. In a report issued on May 26, Stifel Nicolaus also maintained a Buy rating on the stock with a $87.00 price target.
